News Articles

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare... OSAKA, Japan & CAMBRIDGE, Mass. -Tuesday 11 January 2022  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the...

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies... -Tuesday 11 January 2022  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1...

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721 -Wednesday 22 December 2021  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral...

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of... -Wednesday 8 December 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present a total of 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia....

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in... -Wednesday 8 December 2021  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R)...

Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People... -Wednesday 24 November 2021

- In the Phase 3 SOLSTICE study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level < LLOQ at Week 8 with LIVTENCITY (56%; n=131/235), compared to those treated with conventional antiviral...

Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange... -Tuesday 2 November 2021

Takeda applied for selection to the "Prime Market" of the TSE Corporate Governance Report based on the revised Corporate Governance Code also filed with TSE Published updated corporate governance related documents to help enhance transparency of its corporate...

Takeda Announces Acquisition of Own Shares -Saturday 30 October 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph...

Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global... -Saturday 30 October 2021

Delivered H1 Year-Over-Year Growth in Reported Revenue of +12.8% and Underlying Revenue of +6.8% 14 Global Brands Represent 42% of Total Core Revenue with +11.4% Underlying Growth in H1; Further Acceleration Expected through H2 Highly Innovative Pipeline Poised to Deliver Over the Short-...

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies... -Friday 29 October 2021  

− Acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging γδT cells for the potential treatment of solid tumors and hematological malignancies − As result of successful “build-to-buy” collaboration, Takeda to exercise...

FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients... -Friday 8 October 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory...

Takeda Provides Update on TAK-994 Clinical Program -Thursday 7 October 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients...

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals -Tuesday 5 October 2021  

− JR-141 is a potentially transformative therapy designed to deliver proteins to the brain and peripheral tissues to treat neuronopathic features along with somatic symptoms of Hunter syndrome via intravenous administration − Takeda to exclusively commercialize JR-141 outside the U.S....

Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen... -Thursday 23 September 2021

- Global employees based across 80 countries and regions voted to support new partnerships with IntraHealth International, Jhpiego, Pathfinder International and the World Food Programme - New partnerships bring total Global CSR Program contributions to JPY 16.5 billion across 20 programs in...

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for... -Friday 17 September 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer...

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial -Friday 3 September 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether...

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the... -Thursday 5 August 2021

− The Phase 3 HELP Study™ Open-label Extension (OLE) showed preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks by 87.4 percent overall compared to baseline over the course of approximately 2.5 years − TAKHZYRO use demonstrated a...

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from... -Tuesday 3 August 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee...

Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued... -Monday 2 August 2021

Delivered Year-over-Year Growth in Reported Revenue of +18.4% and Underlying Revenue of +3.8%, Driven by 14 Global Brands Grew Reported Operating Profit of 248.6 Billion Yen ($2.2B) and Solid Underlying Core Operating Profit Margin of 30.5% While Increasing R&D Investments Paid 242.9...

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage... -Saturday 31 July 2021  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate....